Intellia Therapeutics to Present Longer-Term Data from the Ongoing Phase 1 Clinical Trial of Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy

globenewswire

Intellia Therapeutics to Present Longer-Term Data from the Ongoing Phase 1 Clinical Trial of Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy – NEWSnet – News… as it used to be

More Press Releases

May 2, 2026

Crypto Update: Pepeto Announces Exchange Update While XRP Price Prediction $10,000 Target Faces a Reality Check

May 2, 2026

Elektros Ignites a New Era of Profit in Energy: Breakthrough ‘Energy Core’ Platform Positions Investors to Capture Massive Upside Amid Historic Utility Cost Surge

May 2, 2026

NomosLogic Founder Matt Hardy Launches Lyceum and Odyssey on Dendrite Lite

May 2, 2026

Intellia Therapeutics to Present Longer-Term Data from the Ongoing Phase 1 Clinical Trial of Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy

Crypto Update: Pepeto Announces Exchange Update While XRP Price Prediction $10,000 Target Faces a Reality Check

Elektros Ignites a New Era of Profit in Energy: Breakthrough ‘Energy Core’ Platform Positions Investors to Capture Massive Upside Amid Historic Utility Cost Surge

NomosLogic Founder Matt Hardy Launches Lyceum and Odyssey on Dendrite Lite

Older Home Electrical Risks? Burlington ON Electricians Explain What to Know